---
title: "Novoprotein expects a pre-loss, with a projected net loss of 60 million to 45 million yuan in 2024"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/225330932.md"
description: "Novoprotein expects a net loss of between 60 million and 45 million yuan in 2024, a loss compared to the same period last year. The company mentioned in the announcement that due to external environment, changes in market demand, and cyclical adjustments in the industry, the product sales structure has changed. To enhance core competitiveness, the company will increase investment in product quality improvement"
datetime: "2025-01-17T10:17:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/225330932.md)
  - [en](https://longbridge.com/en/news/225330932.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/225330932.md)
generator: "portal-rs"
---

# Novoprotein expects a pre-loss, with a projected net loss of 60 million to 45 million yuan in 2024

According to the announcement from Novoprotein (688137.SH), the company expects to report a net loss attributable to the parent company's owners for the fiscal year 2024, compared to the same period last year (statutory disclosure data), with a projected net loss ranging from 60 million to 45 million yuan.

During the reporting period, the company continuously enriched its product lines of target proteins, cytokines, recombinant antibodies, enzymes, and reagents, while continuously improving and strengthening its full-process solutions for segmented application markets. The company's product sales structure has changed due to ongoing impacts from external environments, market demand fluctuations, and industry cyclical adjustments. To further solidify its core competitiveness in recombinant proteins, the company has continued to increase investments related to product quality enhancement. These factors have led to a decline in net profit and net profit excluding non-recurring gains and losses compared to the same period last year

### Related Stocks

- [688137.CN](https://longbridge.com/en/quote/688137.CN.md)

## Related News & Research

- [Coffee Prices Extend Losses as Supply Fears Ease](https://longbridge.com/en/news/297210653.md)
- [Oryzon Genomics wins US notice of allowance for iadademstat-gilteritinib AML patent application](https://longbridge.com/en/news/297475261.md)
- [CytoNiche Expands U.S. FDA Regulatory Filings for 3D RecomTrix Recombinant Collagen Microcarriers](https://longbridge.com/en/news/297358302.md)
- [Coffee Prices Plunge in Anticipation of Larger Brazil Supplies](https://longbridge.com/en/news/297067257.md)
- [Prince Silver Builds Momentum Toward Maiden Mineral Resource Estimate After Completing More than 10,000 m of Drilling | PRNCF Stock News](https://longbridge.com/en/news/297174489.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**